Two new Patents issued by USPTO for Cell Source Inc.

Cell Source Inc. announced that they have received two patents for their Veto Cell Technology, which has been issued by the United States Patent and Trademark Office (USPTO). The first patent is the “Veto Cells Generated from Memory T Cells” and the second patent is the “Method of Transplantation and Disease Treatment.”

Veto Cell Technology

Cell Source’s proprietary Veto Cell technology platform is based on a fundamental scientific discovery – the ability to use such veto T cells without the harmful ability of such T cells to induce Graft-versus-Host Disease (GvHD). This enables the attainment of selective immune suppression while leaving the rest of the immune system intact. This selective tolerance by the immune system has many important applications, including making bone marrow and organ transplants safer, more accessible, and more effective, and can have a major impact on improving the efficacy of cancer treatments. Veto Cells accompany transplanted cells or tissue and act as a “bodyguard” by attracting the recipient’s attacking (transplant rejecting) T cells and then killing them before they are able to reach their intended target. This allows for successful transplant acceptance (engraftment), even without a full match between the donor and recipient, and the reduction of powerful immune suppression treatments (radiation and chemotherapy) that are often harmful to the patient. For more information, visit-

cell source

[Image Source: Cell Source Inc.]

What the patent is all about?

The first patent describes those Veto Cells that safely elicit patient acceptance of transplanted cells, such as stem cells, by overcoming the barriers of graft rejection and graft versus host disease (GvHD). On the other hand, the second patent describes those Veto Cells act as unique, powerful companion cells that allow cellular therapies such as CAR-T and NK to be safely tolerated by the patient without transplant rejection or graft vs. host disease (GvHD) – while increasing overall combined treatment impact.

Speaking on the issuance of the patents, Dennis Brown, Chairman of Cell Source said, “These issued patents reiterate the versatility of Veto Cells as a powerful, multi-faceted immunotherapy platform technology. They can act as enablers that improve the duration and efficacy of important cellular therapy treatment methodologies such as the use of CAR-T or NK cells, are capable of fighting bacterial and viral infections that often occur with stem cell transplants, and can be employed in a direct, stand-alone, cancer-fighting capacity. We believe Veto Cells have the potential to play a crucial role in the future for a broad range of adoptive cell therapies, as stand-alone cell therapy, and in combination with other treatments."

The patents increase the overall treatment efficacy of the patients suffering from transplant-related complications whereby the cells work in conjunction with the existing stem cell transplant therapies. It enables the Veto Cells to effectively targeting cancer that have not responded to genetically modified T-cell therapies or where these therapies do not currently exist.

The first patent (US Patent No. 10,961,504 to be issued March 30, 2021) effectively helps the Veto Cells to generate the memory function allowing the cell to effectively recognize the specific targets, including viruses, bacteria, and cancer. The advance put up by the patent is the memory capacity that adds to the Veto Cell beyond their ability to immune system. The memory in the Veto Cells comes up with the prior exposure to the antigen.  A Phase 1/2 clinical trial is currently in progress testing the safety and efficacy of Cell Source's Veto Cells in patients with hematological cancers or with non-malignant hematological diseases.

The second patent (US Patent No. 10,933,124, issued March 2, 2021) enables the Veto Cell to allow the transplanted mismatched donor cell, including treatment cells to achieve "safe passage" through the patient's immune system while avoiding transplant-related issues such as GvHD. It helps to ensure that the patient’s immune system fully accepts and integrates the treatment cell.

Cell Source centers itself with the cellular therapy and immunotherapy platform technologies for treating blood cancer and more accessible bone marrow transplantation (BMT). Being an exclusive innovator of Veto Cells, it also works for the correction of non-malignant genetic blood disorders like sickle cell disease and to durably treat autoimmune diseases such as type-one diabetes. The company is working on a broader perspective for developing safe and curative BMT.

Author: Saransh Chaturvedi an associate at Global Patent Filing,  in case of any queries please contact/write back us at

Get In Touch

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.